Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Direct exposure of the head to solar heat radiation impairs motor-cognitive performance

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fighting Cancer Using an Oncofetal Glycosaminoglycan-Binding Protein from Malaria Parasites

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

In Africa, cervical cancer and placental malaria (PM) are a major public health concern. There is currently no available PM vaccine and the marketed Human Papillomavirus (HPV) vaccines are prohibitively expensive. The idea of a combinatorial HPV and PM vaccine is attractive because the target population for vaccination against both diseases, adolescent girls, would be overlapping in Sub-Saharan Africa. Here we demonstrate proof-of-concept for a combinatorial vaccine utilizing the AP205 capsid-based virus-like particle (VLP) designed to simultaneously display two clinically relevant antigens (the HPV RG1 epitope and the VAR2CSA PM antigen). Three distinct combinatorial VLPs were produced displaying one, two or five concatenated RG1 epitopes without obstructing the VLP's capacity to form. Co-display of VAR2CSA was achieved through a split-protein Tag/Catcher interaction without hampering the vaccine stability. Vaccination with the combinatorial vaccine(s) was able to reduce HPV infection in vivo and induce anti-VAR2CSA IgG antibodies, which inhibited binding between native VAR2CSA expressed on infected red blood cells and chondroitin sulfate A in an in vitro binding-inhibition assay. These results show that the Tag/Catcher AP205 VLP system can be exploited to make a combinatorial vaccine capable of eliciting antibodies with dual specificity.

Original languageEnglish
JournalScientific Reports
Volume9
Issue number1
Pages (from-to)5260
ISSN2045-2322
DOIs
Publication statusPublished - 27 Mar 2019

ID: 59240052